近年来，血脂异常所致的疾病负担呈持续加重趋势。传统降脂药物降脂疗法疗效有限且部分患者无法耐受，亟需不断开发创新疗法。前蛋白转化酶枯草溶菌素9、载脂蛋白C-III（ApoC3）、血管生成素样蛋白3（ANGPTL3）和脂蛋白a[Lp(a)]是具有遗传学基础的治疗性脂质靶点，已展现出调节血脂异常的潜力。总结了靶向血脂异常关键靶点的核酸疗法药物研究进展，以期为临床精准脂质管理提供参考。

In recent years, the burden of diseases caused by abnormal blood lipids has been continuously increasing. The efficacy of traditional lipid-lowering drugs lipid-lowering therapy is limited and some patients cannot tolerate it, and there is an urgent need to continuously develop innovative therapies. Proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein C-III (ApoC3), angiopoietin-like protein 3 (ANGPTL3), and lipoprotein (a) [Lp(a)] are therapeutic lipid targets with genetic basis, which have shown potential in regulating dyslipidemia. This article summarizes the research progress of nucleic acid therapy drugs targeting key targets of dyslipidemia, in order to provide reference for precise lipid management in clinical practice.

R969;R973